We are delighted to share that our Co-founder and CSO Dr Jordan Lane has been appointed as a new member of the UK Young Academy.
After an incredibly competitive process, the UK Young Academy has selected 22 new members who will join 141 emerging leaders working across disciplines from AI in drug discovery to paediatrics, infectious diseases, and the creative arts.
Members are selected for their track records of excellence and their commitment to shaping the future of research, innovation, and society. This year’s cohort also represents the highest proportion of members from non-academic settings so far, reflecting the Academy’s mission to bring diverse voices together to improve decision-making and mobilise early-career talent.
Dr Jordan Lane said: “I am committed to making science and innovation more inclusive, collaborative, and reflective of the society it is meant to serve and the UK Young Academy provides a framework to do so.”
At Ignota Labs, we strongly believe that interdisciplinary collaboration is essential to solving some of the most complex challenges in science and healthcare. We are proud to see Jordan recognised among a community of leaders who are working across boundaries and building new partnerships for impact.
Congratulations to the 2026 cohort of the UK Young Academy!
About the UK Young Academy
The UK Young Academy connects and develops talented individuals in the early years of their career from a wide range of sectors so they can collaborate to make a difference in the world.
It is part of a growing international initiative to give early-career innovators, professionals, academics, and entrepreneurs a voice for the advancement of issues that are important to them. The UK Young Academy gives its members the chance to have their perspectives, knowledge, and insights represented as part of the wider landscape of academic and professional bodies in the UK.
The UK Young Academy was established following an agreement by the seven senior academies across the UK and Ireland – the Academy of Medical Sciences, British Academy, Learned Society of Wales, Royal Academy of Engineering, Royal Irish Academy, Royal Society of Edinburgh, and the Royal Society. Working closely with the Global Young Academy and the Young Academy of Scotland, it was set up under the auspices of the Royal Society in 2022.
About Ignota Labs
Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hope to patients. More than half of all clinical trials fail due to safety issues, resulting in a staggering $400 billion annual loss and delaying life-saving treatments for patients. Our proprietary platform, SAFEPATH, uses cutting-edge deep learning to address these challenges by uncovering the mechanisms behind drug toxicity. Unlike traditional safety assessments that identify what went wrong, our AI platform SAFEPATH combines cheminformatics, bioinformatics, and multimodal data analysis to explain why and how safety issues occur, delivering actionable insights to refine or repurpose drug candidates. Ignota Labs is building a robust pipeline to bring safer drugs to market faster, partnering to develop and co-develop
Media Contact
Hailey Eustace
hailey@commplicated.com
+44 (0)7872 629 960
